New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2014
08:57 EDTHEBHemispherx to present results to date of Ampligen/FluMist trial
Hemispherx Biopharma announced that the ASM Biodefense Meeting is scheduled for January 27-29 in Washington DC. The University of Alabama and Hemispherx's poster presentation is entitled "Seasonal Influenza Vaccine and a TLR-3 Agonist, Rintatolimod (Ampligen), Given Intranasally Produced Cross-Reactive IgA Antibodies Against Pathogenic H5N1 Influenza HA" and will be provided in poster format by Dr. E. Turner Overton, an infectious disease expert at UAB, in the afternoon of January 29. Representatives of Hemispherx Biopharma and Prof. Overton, the principal researcher conducting the clinical trial at the University of Alabama at Birmingham, will describe the results to date of the Ampligen/FluMist intranasal influenza vaccine clinical trial and address questions during a media conference at the National Press Club in Washington, DC scheduled on Thursday, January 30.
News For HEB From The Last 14 Days
Check below for free stories on HEB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
08:41 EDTHEBHemispherx achieves high ranking in sensitivity testing against MERS/SARS
Subscribe for More Information
July 14, 2014
08:39 EDTHEBHemispherx, Bioclones announce strategic alliance
Hemispherx Biopharma announced a strategic alliance to develop multiple projects with Bioclones. Bioclones and Hemispherx concluded strategic discussions in Johannesburg with three principal goals; initiating studies utilizing Ampligen as a potential adjuvant enhancement of Bioclones' therapeutic cancer vaccine, currently in clinical trials in Cape Town, including pre-clinical studies followed, potentially, by a Phase 1 clinical trial; seeking South African Medicine's Control Council approval to conduct trials using Alferon to eradicate the HIV virus in patients highly responsive to anti-retroviral therapy; and initiating a joint effort to obtain commercial registration of both Ampligen and Alferon in the South African markets. The first clinical program builds on the Bioclones patented therapeutic human dendritic cell, or DC, cancer vaccination approach. This invention provides a method of producing mature DCs in vitro, which comprises the step of culturing the immature DCs, thereafter exposing said cells to tumor antigens before administration to patients. The team has successfully obtained the necessary Ethics approval to use Ampligen as an adjuvant in the Bioclones pre-clinical cancer immunotherapy program utilizing patient derived samples. Pre-clinical studies will be directed towards the potential treatment of breast cancer in particular, followed by prostate cancer. These studies are part of the effort to develop patient-specific DC immunotherapy vaccines against breast cancer and prostate cancer, which elicit an immune response that will target and kill cancer cells. Human DCs matured with Ampligen and transfected with autologous tumor-specific mRNA are designed to elicit a potent and autologous tumoricidal antigen-specific cytotoxic response to the cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use